International Journal of Pharmaceutical Chemistry and Analysis 2023;10(3):144–149 Content available at: https://www.ipinnovative.com/open-access-journals International Journal of Pharmaceutical Chemistry and Analysis Journal homepage: https://www.ijpca.org/ Review Article Overview: Versatility of curcumin in management of diabetic retinopathy Layba Sayyad 1 , Amit Kakad 2, *, Hemant Raut 2 , Savita Jagtap 2 , Amruta Sonawane 2 , M.R.N Shaikh 2 , Atul Bendale 3 1 MET’s Institute of Pharmacy, Nashik, Maharashtra, India 2 MET’s Institute of D Pharmacy, Nashik, Maharashtra, India 3 Shree Mahavir Institute of Pharmacy, Nashik, Maharashtra, India ARTICLE INFO Article history: Received 19-07-2023 Accepted 29-08-2023 Available online 15-09-2023 Keywords: Diabetic retinopathy Diabetic macular edema Curcumin Proliferative & Non-proliferative. ABSTRACT Introduction: On a worldwide scale, the diabetic retinopathy (DR) is listing the primary causes of the loss of sight in the individuals. The main reason behind the occurrence of DR is diabetes mellitus (DM) and diabetic macular edema (DME). Diabetic retinopathy have some types of it i.e Non- proliferative diabetic retinopathy (NPDR) and Proliferative diabetic retinopathy (PDR). Where NPDR is an initial stage and PDR is the severe stage where the person loss the eye sight due to various factors which causes changes in the retinal micro vascularisation. Materials and Methods: Use of Curcumin in Diabetic Retinopathy may help as a treatment and preventive action for all the stages of DR with its active constituent in various ways. We are focusing on some highlights of curcumin as an active drug to prevent and management of the DR. Results and Conclusions: As the given review presenting the versatility of natural source of medicine like a curcumin can be the best choice of drug for diabetic retinopathy due to its various effects like protect the loss of retinal ganglionic cells, neuroprotective effect by inhibiting oxidative damage to microglia, also act as anti- inflammatory agent, anti VEGF agent, a recognized PPAR-gamma agonist. Hence, In future Curcumin can be preferably useful for management of all the stages involved in Diabetic Retinopathy. This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. For reprints contact: reprint@ipinnovative.com 1. Introduction Diabetic Retinopathy is currently the most popular microvascular consequence of diabetes, and it is still one of the leading causes of blindness in adults aged 20 to 74 worldwide. The two most prevalent visual outcomes of DR are proliferative DR (PDR) and diabetic macular edema (DME). Almost all individuals with Type 1 diabetes and more than 60–70 percent of those with Type 2 diabetes have some kind of retinopathy after 20 years. 1 It’s been classified as a microvascular illness of the retina, and it’s characterised by aberrant retinal vessel development that leads to * Corresponding author. E-mail address: amitkakad12@gmail.com (A. Kakad). haemorrhages and tractional retinal detachment, resulting in visual loss. 2,3 Diabetic complications, in an additional factor to the core illness, are predicted to have far-reaching consequences for patient care in the future. Diabetes is a hyperglycemic condition, and DR is the outcome of the retina’s microvascular deterioration over time. The WHO estimates that DR accounts for around 5% of all blindness worldwide.Aside from the fact that laser photocoagulation treatment has long been the standard of care, the use of intravitreal VEGF medicines and steroids has revolutionised diabetic macular oedema treatment in recent years. 4,5 Diabetic retinopathy (DR) is a metabolic disorder and a long-term inflammatory disease in which the retina’s blood vessels and photoreceptors are destroyed. The vasculature https://doi.org/10.18231/j.ijpca.2023.026 2394-2789/© 2023 Innovative Publication, All rights reserved. 144